Anthony Coyle (Repertoire)
Flagship's merged biotech Repertoire nets ex-Pfizer CSO Anthony Coyle as R&D chief
Flagship is building a big-name C-suite at its new, $220 million merged biotech.
Repertoire Immune Medicines, which already boasts former Bioverativ chief John Cox as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.